Diminazene aceturate prevents nephropathy by increasing glomerular ACE2 and AT₂ receptor expression in a rat model of type1 diabetes.

ABSTRACT:

Background and purpose

One of the protective actions of angiotensin converting enzyme-2 (ACE2) is the inactivation of angiotensin II. Expression and activity of ACE2 was reduced in glomeruli of diabetic patients and in animal models of diabetes. Recently the potential role of recombinant ACE2 administration in preventing diabetic nephropathy (DN) has been shown. Here we have tested the effects of the ACE2 activator, diminazene aceturate (DIZE), in a model of DN.

Experimental approach

Male Wistar rats were rendered diabetic using a single dose of streptozotocin (55 mg·kg^-1 , i.p.). After 4 weeks, diabetic animals were divided into experimental groups and treated with DIZE, at a low dose (5 mg·kg^-1 ·day^-1 ), a high dose (15 mg·kg^-1 ·

SUBMITTER: Goru SK 

PROVIDER: S-EPMC5573423 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature